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Preface
An agreement has been signed by the Dutch Expert Committee on Occupational
Standards (DECOS) of the Health Council of the Netherlands and the Nordic
Expert Group for Criteria Documentation of Health Risks from Chemicals (NEG).
The purpose of the agreement is to write joint scientific criteria documents which
could be used by the national regulatory authorities in both the Netherlands and in
the Nordic Countries.
The document on health effects of 1,2,3-benzotriazole was written by H. Stouten,
A.A.J.J.L Rutten, I.A. van de Gevel, and F. De Vrijer from the Toxicology Division
of TNO Nutrition and Food Research, Zeist, the Netherlands and has been reviewed
by DECOS as well as by NEG.
The document has been adapted to the different formats used by DECOS and NEG.
G.J. Mulder G. Johanson
Chairman Chairman
DECOS NEG
Abbreviations
bw body weight
h hour
CI confidence interval
LC50 lethal concentration for 50% of the exposed animals
LClo lowest lethal concentration
LD50 lethal dose for 50% of the exposed animals
LDlo lowest lethal dose
LOAEL lowest observed adverse effect level
NOAEL no observed adverse effect level
ppm parts per million (v/v)10-6, cm3/m3
UV ultraviolet
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11. Introduction
Benzotriazole is an odourless, white to tannish crystalline powder. It is sparingly
soluble in water and soluble in a number of organic solvents. It has a low vapour
pressure, and it is therefore likely to occur as dust at the workplace. When finely
divided and mixed with air, dust explosions may occur.
Benzotriazole is an industrial compound primarily used as a corrosion inhibitor,
as a plastic stabiliser, and as a chemical intermediate.
In the present report, the consequences of occupational exposure to 1,2,3-
benzotriazole (further referred to as benzotriazole) are discussed.
2. Identity, properties and monitoring
2.1 Identity
2.1.1 Structure
2.1.2 Chemical names and synonyms/registry numbers
Name benzotriazole
CAS registry number 95-14-7
CAS index name 1H-benzotriazole
Synonyms 1,2,3-benzotriazole; benzisotriazole;
benztriazole; 1,2-amino-azophenylene;
azimidobenzene; aziminobenzene; benzene
azimide; 2,3-diazaindole; 1,2,3-triaza-1H-indene;
1,2,3-triazaindene; benzene azimide; 2,3-
diazaindole
EINECS No. 202-394-1
RTECS No. DM1225000
N
N
H
N
22.2 Physical and chemical properties (5, 12, 18, 27)
Molecular formula C6H5N3
Molecular weight 119.14
Boiling point (101.3 kPa) 350°C
Melting point (101.3 kPa) 99°C
Relative density (water = 1) 1.4
Vapour density (air = 1) 4.1
Vapour pressure
(20°C; 101.3 kPa)
<0.01 kPa
Relative density of
saturated vapour/air
mixture (air = 1; 20°C)
1.00
Auto-ignition temperature 400°C
Explosive limits (%, in air) 2.4-?
Solubility in water (25°C) 2.0 g/100 ml
Solubility in organic
solvents
soluble in alcohol, benzene, toluene,
chloroform, dimethylformamide
Partition coefficient
(Log P octanol/water)
1.44 (experimental value)
Physical form white to tan, crystalline powder; needles
when crystallised from benzene
Odour odourless
Benzotriazole exists in two tautomeric forms. The first tautomer has the formula
1H-benzotriazole. The second tautomer has the formula 2H-benzotriazole and is
also referred to as pseudo-azimidobenzene or 2,1,3-benzotriazole. The 1H-
tautomer represents the more stable and essentially exclusive molecular structure
(12).
Dust explosions can occur when finely divided powder is mixed with air. It can
explode when heated and during vacuum distillation. When heated or combusted,
benzotriazole decomposes into toxic vapours (nitrogen dioxide). It is very stable
toward acids and alkalis, and toward oxidation and reduction.
2.3 Validated analytical methods
2.3.1 Environmental monitoring
No method for monitoring benzotriazole in air is available. However, since
benzotriazole will hardly vaporise at room temperature, it will be present as dust,
and general dust measurement methods should be applicable. The benzotriazole
content in the dust may be assessed by analytical-chemical methods after
extraction with a suitable solvent. In view of the specificity and the height of the
detection limit, UV-spectrophotometry, high performance liquid chromatography,
or gas chromatography-mass spectrometry may be most appropriate (see section
2.3.2).
32.3.2 Biological monitoring
No method for the determination of benzotriazole in biological samples was
found.
Gas chromatography-mass spectrometry, high performance liquid chromato-
graphy, and spectrophotometric methods for the determination of benzotriazole in
aqueous solutions have been published (12, 19).
No validated method for biological monitoring of workers exposed to benzo-
triazole was found.
3. Sources
3.1 Natural occurrence
No data available.
3.2 Man-made sources
3.2.1 Production
Benzotriazole is produced by reaction of o-phenylenediamine with nitrous acid in
the presence of glacial acetic acid or by reaction of hydrochloric acid or nitrous
acid with o-phenylenediamine. The production of benzotriazole in the US was
mentioned to be probably higher than approximately 7 and 4.5 tonnes in 1977
and 1979, respectively (27).
3.2.2 Uses
Benzotriazole is used as a corrosion inhibitor, as a plastic stabiliser, and as a
chemical intermediate for dyes, pharmaceuticals, and fungicides. Derivates of
benzotriazole are used as UV absorbers and as restrainers in photographic
emulsions (27).
Benzotriazole is used in metalworking and art restoration as an anticorrosive,
and in the construction industry as a tarnish remover and a protective coating of
metal. It functions as a corrosion inhibitor in water cooling systems such as
automobile radiators and boilers, and in dry cleaning equipment. It is included in
some formulations of automatic dishwater detergents to prevent tarnishing of
metal pots and silverware, and to inhibit the corrosion of metal machine parts.
Benzotriazole is used in synthetic greases, lubricants, and hydraulic fluids to
prevent the oxidation of these materials, which is catalysed by metal ions. In the
electronics industry, it is used to treat packing materials for copper electronic
parts, and to extend the life of polymers that are used as insulators for copper
wire. Furthermore, benzotriazole is used in electrolytic processing, where the
stripping of metals from copper cathodes is eased by pre-treatment of the cathode
with benzotriazole. In photographic processing, benzotriazole acts as an anti-
fogging agent in silver-halide emulsions, restraining the developer and preventing
the blackening or fogging of the image due to overdevelopment (25).
4Coolant lubricants and corrosion inhibiting fluids may contain up to 0.05%
benzotriazole (17, 24).
4. Exposure
4.1 General population
No data available.
4.2 Working population
No data available.
5. Toxicokinetics
There is very little information found with respect to the toxicokinetics of
benzotriazole.
5.1 Absorption
Based on its molecular weight (119.14) and its partition coefficient (log P
octanol/water), dermal absorption might be expected.
Because benzotriazole is a weak base (pK=1.6) as well as a weak acid
(pKa=8.57) (1), a low degree of ionisation of benzotriazole can be predicted at the
physiological pHs of stomach, intestine, and blood, suggesting that it would easily
pass the respective membranes. It is, however, noticed that other factors than
passive diffusion play a role in passing membranes.
5.2 Distribution
No information available.
5.3 Biotransformation
Benzotriazole was incubated for one hour with a microsome suspension obtained
from phenobarbital-induced rat livers at a final concentration in the incubation
solution of 0.2 mg/ml. During this one-hour incubation period, the overall meta-
bolism of benzotriazole was relatively low (<5% of the amount added to incubation
mixture), and the 5-hydroxy metabolite of benzotriazole was formed 4-5 times
more than 4-hydroxybenzotriazole (1.6 vs. 0.32% of the amount added) (22).
5.4 Excretion
No information available.
55.5 Biological monitoring
No information available.
5.6 Summary
No information was found on distribution, excretion, and biological monitoring.
Based on physico-chemical data (molecular weight, partition coefficient), dermal
absorption might be expected. In vitro, using a rat liver microsomal suspension
and an incubation period of one hour, benzotriazole is metabolised to 4- and 5-
hydroxybenzotriazole at a low rate.
6. Effects
6.1 Observations in man
6.1.1 Irritation and sensitisation
Four cases of contact dermatitis among workers exposed to benzotriazole-
containing industrial oils or greases showed positive reactions (varying from
weakly to strongly positive) in a patch test using 2% benzotriazole in petrolatum
(14). However, since there were no data on negative controls and an immuno-
logical reaction was not ascertained, it is not possible to assess whether the effects
were the consequence of irritation or sensitisation.
Forty out of 286 workers from ten Dutch metalworking factories had contact
dermatitis of the hands and/or forearms. Benzotriazole was not listed among the
compounds that induced contact allergy in eight out of these 40 workers upon
patch-testing (4).
In conclusion, based on the available data on humans, an irritating and/or sensi-
tising potential of benzotriazole cannot be excluded.
6.1.2 Toxicity due to experimental or occupational exposure
No data available.
6.2 Animal experiments
6.2.1 Irritation and sensitisation
Eye
Referring to unpublished industrial reports from the mid 1970s, it was stated that
100 mg of benzotriazole instilled into one eye of rabbits (n=6) produced severe
irritation effects, amongst others complete corneal opacity and severe chemosis
(swelling of lids) in four animals. Immediate washing with water greatly reduced
the irritation (2, 12).
In an unpublished study, benzotriazole (granules; "Preventol CI-8"; purity
(from (20)): 99.83%) was slightly irritating to the eyes of female albino rabbits
(New Zealand White; n=3). The study was performed to corresponding OECD
and EU guidelines. When 100 µl of the test substance was instilled into the
6rabbit's eye, left there for 24 h before washing out, the following Draize scores
were obtained (28):
Scoresa observed after: 1 h 24 h 48 h 72 h 7 days
cornea
opacity 1,1,1 1,1,1 1,0,1 0,0,0 0,0,0
iris 1,1,0 1,0,0 1,0,0 0,0,0 0,0,0
conjunctivae
redness
chemosis
discharge
1,1,1
2,2,3
2,2,2
1,1,2
1,2,1
2,2,0
2,1,2
1,0,0
1,0,0
1,0,1
0,0,0
0,0,0
0,0,0
0,0,0
0,0,0
a
 Figures are irritation scores per animal. Grades for scoring range from 0-2 for iris, 0-3 for
  conjunctival redness and from 0-4 for corneal opacity and conjunctival chemosis and
  discharge.
Skin
In an unpublished study, benzotriazole (granules; "Preventol CI-8"; purity (from
(20)): 99.83%) was not irritating to the skin of female albino rabbits (New
Zealand White; n=3). The study was performed to corresponding OECD and EU
guidelines. No erythema or oedema - all scores were 0 - was observed when
500 mg test material (vehiculum: water) was applied under semi-occlusive
conditions for 4 h to the intact clipped skin (observation times: 1, 24, 48, and 72 h
and 7 and 14 days) (28).
Benzotriazole and commercial benzotriazole (purity: unknown) were only
minimally irritating (primary irritation index: 1.0, and 0.7, respectively; maximum
score: 8.0) when applied to the abraded and intact, clipped skin (under 24-h
occlusion) of New Zealand white rabbits (n=3/sex) at a concentration of 50% in
polyethylene glycol (PEG 400) and saline (70:30) (6, 9).
Referring to unpublished industrial reports from the mid 1970s, it was men-
tioned that benzotriazole was mildly irritating to guinea pig skin at a concentration
of 50% in ethanol. Furthermore, in a separate experiment, no irritation was
reported after 24 and 72 h (no other evaluation time points mentioned) when about
80 mg/cm2 (of the pure material) was administered to the intact or abraded skin of
rabbits (n=6/group) and covered for 24 h. However, there were signs of irritation,
consisting of a well defined but transient erythema observed at experimental day
2, in three out of five rabbits following 24-h covered contact with 2000 mg/kg bw
applied to abraded skin (observation period: 14 days) (2, 12).
Sensitisation
In an unpublished study, benzotriazole ("Benzotriazol Granulat"/"Preventol CI-8";
purity: 99.83%) was not a skin sensitiser when tested in male guinea pigs
(Winkelmann DHPW; n=20; controls: n=10) using the Magnusson-Kligman
maximisation test. The study was performed according to corresponding OECD
and EU guidelines (good laboratory practice statements were included). A positive
control group treated with formaldehyde was included to demonstrate the
sensitivity of the test. Following an intradermal and topical (one week later)
induction of a 5 and 25% solution in propylene glycol, respectively, an epidermal
7challenge application of a 12% solution, three weeks later, caused a positive
reaction in 1/20 animals. This positive response was, however, very weak. It was
observed only 24 h after challenge and not confirmed by the 48-h observation. In
the control group, a weak positive response was found in 1/10 animals at the 24-h
observation (20).
In guinea pigs, the optimisation test showed negative results with purified and
commercial (purity: unknown) benzotriazole after intradermal as well as epi-
dermal challenge application. In the maximisation test, negative results were
obtained with purified benzotriazole (exact composition not known), but an
epidermal challenge application of 30% of commercial benzotriazole caused slight
erythemas in 3/20 animals (controls: 0/19) (24). In two other, not published
studies (industrial reports from the mid 1970s), it was reported not to be a skin
sensitiser when tested in guinea pigs (no experimental details presented) (2).
Conclusion
From data with benzotriazole of known purity, it is concluded that, in experi-
mental animals the compound is slightly irritating to the eyes and, at most, slightly
irritating to the skin. In addition, benzotriazole is apparently not a skin sensitiser.
6.2.2 Acute toxicity
When rats (male; n=10/group) were exposed during 3 h to benzotriazole aerosols of
780, 1460, 2030, 2230, and 2710 mg/m3 (no data on particle size, particle size
distribution humidity, etc), mortality was 10%, 20%, 50%, and 100%, respectively.
Almost all animals died during the exposure period, usually during the first half-
hours, and showed severe accumulation of white frothy liquid in the trachea and
haemorrhages in the lungs. There was no pulmonary oedema. In the surviving
animals, the only sign of intoxication observed was deep abdominal breathing and
open mouth gasping in the animals exposed to the two highest concentrations. From
these mortality data, an LC50 of 1910 mg/m3 (95% CI: 1590-2290 mg/m3) was
presented (see 2, 12). [In view of the experimental data, an LC50 of 2153 mg/m3
(95% CI: 1908-2402 mg/m3) seems more reasonable.]
Dermal LD50 values were reported to be greater than 1000 and 2000 mg/kg bw
in rats (26) and rabbits (2), respectively. Only the rabbit study was described in
more detail. Apart from skin irritation (see also section 6.2.1), no other toxic
effects were reported. However, histological examinations were not included, and
the absence of a control group prevented the evaluation of body weight gain data
(12).
Oral LD50 values ranged from 500 to 965 mg/kg/bw in rats, whereas in mice
oral LD50s of 615 (26), 831 (17) and greater than 4500 mg/kg bw (2) have been
mentioned. In guinea pigs, it was estimated to 500 mg/kg bw (26). No description
of toxic effects was given. In a range-finding toxicity test preceding an unpub-
lished micronucleus test (see also section 6.2.5), single oral (gavage) doses of 500,
750, 850, and 1000 mg/kg bw of benzotriazole (granules; "Preventol CI8-100";
purity: 99.83%) to male and female NMRI mice caused mortality in the two
higher dose groups (850 mg/kg: 2/5; 1000 mg/kg: 3/5). Symptoms observed
included apathy, reduced motility, unkempt coat, lateral position, abdominal
8position, cramp, convulsion, and rapid breathing. Data relating incidence/severity
and dose levels were not given (21).
Intraperitoneal LD50 values ranged from 500-900 and 500-1000 mg/kg bw in
rats and mice, respectively. In mice, effects on the central nervous system
(convulsions; flaccid paralysis) were seen at doses of approximately 250 mg/kg
bw. Following single intravenous injections to mice, an LD50 was found to be
238 mg/kg bw, while effects on the central nervous system (reduced reflexes;
paralysis) were observed at a dose of 55 mg/kg bw. In mice, intravenous and
intraperitoneal doses caused death by respiratory arrest (2).
In conclusion, based on the acute lethal toxicity data (inhalation LC rat∗:
2153 mg/m3; oral LD50 rat: 500-965 mg/kg) and using EC-classification criteria,
benzotriazole is considered harmful following inhalation and oral exposure. Oral
and intraperitoneal LD50s in rats and mice were of similar order of magnitude
(500-1000 mg/kg bw).
6.2.3 Short-term toxicity (up to 90 days)
In a pilot experiment prior to a carcinogenicity study, groups of male (n=5) and
female (n=5) rats (Fischer 344) and mice (B6C3F1) were fed benzotriazole at
concentrations of 300, 1000, 3000, 10 000, and 30 000 ppm (rats: approximately
13-1325 mg/kg bw/d; mice: approximately 37-3710 mg/kg bw/d)∗∗ in the diet for
eight weeks. This experiment was performed in order to estimate the maximum
tolerated dose. It was not reported which end points were investigated, and only
statements on survival and body weight were presented. In rats, body weight
decreases∗∗∗ were not higher than 12% at each dose ranging from 300 to
10 000 ppm, while a sharp decrease of 34-40% in body weight was observed at
30 000 ppm. All animals survived. In mice, a small effect on body weight (i.e.,
a decrease of approximately 5%) was observed at a concentration of 30 000 ppm
only (25). However, considering the low number of animals used and the limited
scope (range finding for a 2-year carcinogenicity study) and reporting (only
statements on survival and body weight), no conclusions regarding a NOAEL can
be drawn from this study.
Undefined toxic effects on the peripheral blood system, liver, and kidney
were observed in rats (sex not known) after oral administration of 2.4, 12, and
60 mg/kg bw/day for 30 days. A daily oral dose of 0.6 mg/kg bw for six months
induced toxic effects (not specified), while 0.06 mg/kg bw/day did not (original
paper in Russian). No further details were reported (17), and therefore this study is
not suitable for evaluation of the health hazard.
The available short-term toxicity studies suffer from various limitations that
exclude them from being used for health hazard assessment purposes.
                                    
∗ This value was calculated by DECOS from the experimental data presented in (2) and (12)
(see section 6.2.2).
∗∗
 To convert oral doses from ppm or mg/kg diet into mg/kg bw the following default values (or
their averages) are used throughout this report: rat male bw 500 g, daily food intake 20 g;
female bw: 350 g, daily food intake 17.5 g; mouse male bw 30 g, daily food intake 3.6 g;
female bw 25 g, daily food intake 3.25 g.
∗∗∗ Probably decreased body weight gain was meant.
96.2.4 Long-term toxicity and carcinogenicity
In a carcinogenicity study, male and female rats (Fischer 344; n=50/sex/group)
were fed time-weighted average doses of 6700 and 12 100 ppm (i.e., approxima-
tely 295 and 535 mg/kg bw/day; dosage adjusted during the experimental period)
for 78 weeks. This was followed by an observation period of 27 weeks. Animals
were observed twice daily for signs of toxicity, clinical observations were
recorded every month, and body weights were recorded every two weeks for the
first twelve weeks and every month thereafter. The pathological evaluation
consisted of gross and microscopical examinations of major tissues, major organs,
and all gross lesions from killed animals and from animals found dead. Data on
both neoplastic and nonneoplastic lesions were presented. No data on organ
weights were given. Consistently lower mean body weights were found in the
exposed groups when compared with controls (only growth curves presented). In
male rats, survival rates were not affected by treatment, while in dosed females
survival was slightly higher than in controls. No compound-related clinical signs
were seen. At post-mortem examinations, nonneoplastic lesions observed were:
inflammation of the prostate and the uterus and changes in the liver ("clear-cell
changes", "basophilic cytoplasm change", "eosinophilic cytoplasm change").
With respect to neoplastic lesions, benign liver tumours (nodules), not present
in either the control or low-dose male rats, were seen in five out of the 45 (11%)
high-dose males, a statistically significant increase. However, since incidences of
10-11% had been seen in two out of thirteen groups of untreated rats of the same
strain at the same laboratory (in previous experiments), the investigators con-
cluded that the tumours "cannot be clearly associated with administration of the
test chemical". There were brain tumours in three out of the 44 (7%) low-dose
males and in one out of the 50 (2%) high-dose females, but neither in male nor in
female controls. Previous results, from the same laboratory, showed a low inci-
dence of brain tumours in untreated rats of the same strain (none in 250 males and
one in 249 females studied). The investigators concluded that the tumours were
"suggestive of, but not considered as sufficient evidence of, carcinogenicity". The
low-dose females had a significantly higher level of benign uterus tumours com-
pared with the controls (10/45 or 22% vs. 2/48 or 4%). However, since the 16%
incidence in the high-dose group did not attain statistical significance, the investi-
gators concluded that these tumours "cannot be associated with administration of
the chemical" (25). In addition, incidences of 12-15% had been seen in untreated
groups of the same strain of rat in other laboratories (2). Benign thyroid tumours
were seen in four out of the 43 (9%) low-dose female rats while malignant thyroid
tumours occurred in one out of the 43 (2%) low-dose and three out of the 50 (6%)
high-dose females. These tumours were not present in the female controls (25).
Previous results, in other laboratories (again with the same strain), have shown the
incidence of these types of benign and malignant thyroid tumours in untreated
female groups to be 4-5% and 1-4%, respectively (2). The above results, there-
fore, may indicate a weak carcinogenic action at this site, although the investi-
gators do not discuss these findings. There was no statistically significant increase
in thyroid tumour incidence in the male rats (25).
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A similar carcinogenicity study was performed in mice (B6C3F1; n=50/sex/group)
according to a similar protocol. When fed average time-weighted doses of 11 700
and 23 500 ppm (i.e., ~1455 and ~2925 mg/kg bw/day; dosage adjusted during the
experimental period) for 104 weeks followed by an observation period of two weeks,
mean body weights were dosis-relatedly decreased (only growth curves presented).
As in rats, survival rates were affected in dosed females (i.e., higher) only, and there
were no clinical signs. Treatment-induced nonneoplastic changes were found in the
bone marrow (myelofibrosis) and mesenteric lymph nodes (haemorrhages). No
convincing evidence of carcinogenicity was seen. However, a higher number of lung
tumours were found in the treated females; incidences in the controls, low-dose, and
high-dose animals being 0, 9, and 3 out of 49, respectively (0%, 18%, 6%, respec-
tively). In previous control groups of females kept at the laboratory, the incidences
of these tumours varied from 0 to 7%, with a mean of 4%, which led the investigators
to describe the benzotriazole findings as only suggesting a possible carcinogenic
effect (2, 25).
Death and decreased growth were noted when mice, already suffering from
mammary tumours, were given eleven to fifteen injections (unspecified route) of
50-150 mg/kg bw/day (2). Subcutaneous administration of 100 mg/kg bw/day to
rats, for 46 weeks, caused liver damage (2). No details were reported and there-
fore, this study is not suitable for the evaluation of the health risk.
When 315 male and female mice were administered oral doses of 100 mg/kg
bw weekly for 46 weeks (by stomach tube), an incidence of leukaemia of 13.7%
was reported. This incidence was significantly higher than that of 3.4% which was
observed in a group of untreated mice. However, in a control group, where the
solvent (type unspecified) used for the above dosing was administered alone,
11.1% developed leukaemia (2).
In a tumour promotion study, rats were fed benzotriazole at about 250 mg/kg
bw/day for eight weeks, along with a known liver carcinogen. Benzotriazole had
no effect on the incidence of liver tumours (2).
From the carcinogenicity studies with rats and mice there is inconclusive
evidence that benzotriazole is carcinogenic. Although higher incidences of -
mostly benign - tumours in some organs were observed in treated than in con-
current control animals, these tumours had mostly higher incidences in the low-
dose than in the high-dose group, and occurred at fairly high rates in historical
controls. No NOAEL could be assessed since effects were observed in rats
(neoplastic effects: brain tumours in males, thyroid tumours in females; nonneo-
plastic effects: decreased body weight gain, histological changes in liver cells,
inflammation of prostate and uterus) and mice (neoplastic effects: lung tumours in
females; nonneoplastic effects: decreased body weight gain, bone marrow myelo-
fibrosis, haemorrhages in mesenteric lymph nodes) at the lowest doses tested. This
study resulted in LOAELs of 295 and 1455 mg/kg bw/day in rats and mice,
respectively.
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6.2.5 Genotoxicity
A summary of in vitro genotoxicity studies is presented in Table 1.
Benzotriazole was found mutagenic in one Salmonella typhimurium strain
(strain TA 1535) in the presence of a metabolic activation system (7, 8, 16, 30),
while for this strain both positive (7, 8) and negative (16, 30) results were found in
the absence of a metabolic activation system. In another study, a positive response
was obtained in strain TA1535 in the presence of hamster liver S9 preparations
only (mouse and rat liver S9 gave negative results) (15). When commercial
benzotriazole (purity: unknown) was tested, positive results were obtained in
strains TA98, TA1537, and TA1538 as well (10, 11). In E coli (strainWP2 uvrA),
mutagenicity was observed both in the presence and in the absence of a metabolic
activation system (16).
As to in vitro mammalian cell systems, benzotriazole ("Benzotriazol Granulat"/
"Preventol CI-8"; purity: 99.83%; vehicle: DMSO) was tested in the HGPRT
forward mutation assay in Chinese hamster ovary (CHO) cells. Without adding a
metabolic activating system, negative results were obtained in two independent
trials at dose ranges of 400-1000 µg/ml (5 duplicate doses/trial). In the presence of
an induced rat-liver-derived S9 mix, a slight statistically significant increase in
mutation frequency was observed at one of the mid-dose levels in one of the trials
(dose range: 200-1000 µg/ml; 5 duplicate doses/trial). However, this increase was
within historical control levels, not dose related, and not found in the other trial
(3). In view of the survival rates (approximately 72% at 1000 µg/ml) in the
nonactivating test, higher levels could have been tested. However, from the results
presented for the dose range tested a positive result is unlikely to occur at higher
doses than tested. Thus, (in accordance with (3)) benzotriazole is judged negative
in this assay.
In validating an in vitro transformation assay, which was developed to detect
mutagens/carcinogens by measuring the acquisition of attachment independence
(recognised as being characteristic of transformed cells), benzotriazole was
positive (29).
In vivo, benzotriazole was investigated for its potential to induce clastogenic
effects with the mouse bone marrow micronucleus test. In this unpublished study,
performed according to relevant OECD guidelines, there was no increase in the
incidence of micronuclei in polychromatic erythrocytes obtained from mice
(NMRI; n=5/sex/sacrifice) 24, 48, and 72 hours after administration of a single
oral dose (gavage; vehicle: PEG 400) of 800 mg/kg bw of benzotriazole (granules;
"Preventol CI8-100"; purity: 99.83%). Treatment did not affect the polychromatic/
normochromatic erythrocyte ratio. The level, selected from a preceding range-
finding test, was clearly toxic as was shown by compound-related symptoms such
as apathy, reduced motility, abdominal position, cramp, convulsion, and rapid and
feeble breathing and mortality (in 1/40) (see also section 6.2.2) (21).
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Table 1. In vitro studies of genotoxic effects of benzotriazole
Organism/target cells Endpoint Concentration Metabolic
activation
Res-
ponse
Ref.
TA98, TA100, TA1537, TA1538
TA1535
Gene mutation 33-3333 µl/plate no
yes a
no
yesb
neg
neg
neg
pos
15
TA98, TA100, TA1537, TA1538
TA1535
Gene mutation 0.3-10 000 µl/plate no
yes a
no
yesa
neg
neg
neg
pos
16
TA97, TA98, TA100
TA1535
Gene mutation 33-1666 µg/plate no
yesc
no
yesc
neg
neg
neg
pos
30
TA98, TA100, TA1537, TA1538
TA1535
Gene mutation 444-2250 µg/0.1 ml;
test repeated with
500-8000 µg/0.1 ml
no
yesb
no
yesb
neg
neg
pos
pos
7
TA98, TA100, TA1537, TA1538
TA1535
Gene mutation 25-2025 µg/0.1 ml;
test repeated with
444-2250 µg/0.1 ml
no
yesc
no
yesc
neg
neg
pos
pos
8
TA100
TA98, TA1537, TA1538 d
Gene mutation 25-2025 µg e/ 0.1 ml;
test repeated with
50-4050 µg e/0.1 ml
no
yesc
no
yesc
neg
neg
pos
pos
10
TA100
TA98, TA1535, TA1537, TA1538
Gene mutation 250-4000 µg e/0.1ml no
yesb
no
yesb
neg
neg
pos
pos
11
E. Coli
WP2 uvrA
Gene mutation 0.3-10 000 µg/plate no
yesa
pos
pos
16
E. Coli
PQ37
SOS induction
(DNA damage)
Up to 100 mM or
up to solubility limitf
no
yes
neg
neg
23
Chinese hamster ovary cells HGPRT forward
mutation
50-1000 mg/ml no
yesc
neg
neg
3
a From rat, mouse, and hamster liver (non-induced and Arochlor-induced).
b From hamster liver (Arochlor-induced).
c From rat liver (Arochlor-induced).
d TA1538 used in repeated test only.
e Commercial benzotriazole tested (purity: unknown).
f A great number of compounds were tested at 3-5 different concentrations at half-log intervals at 
a maximum level of 100 mM or the limit of solubility. Specific concentrations per compounds
were not given.
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In conclusion, in vitro, benzotriazole was mutagenic in bacterial cell systems
(Salmonella typhimurium, E coli), but not in mammalian cells (Chinese hamster
ovary cells). An indication test for DNA damage (SOS chromotest in E. coli) was
negative as well. In vivo, benzotriazole did not induce micronuclei in the bone
marrow of orally treated mice. Benzotriazole induced cell transformation.
6.2.6 Reproduction toxicity
In the German documentation, two Russian studies are mentioned in which the
effects of premating exposure of female rats on developmental parameters were
examined. Exposure might have induced changes in hormonal balance (increased
cycles). Data on developmental parameters (foetal and pup mortality, anomalies)
were inconsistent and could not be properly evaluated because they were in-
adequate as well (17).
In conclusion, no valid data on the reproduction toxicity of benzotriazole were
found.
6.3 Summary
Contact dermatitis in metalworkers was observed after skin exposure to benzo-
triazole.
In experimental animals, pure benzotriazole was a slight eye irritant and at most
a slight skin irritant; benzotriazole is not a skin sensitiser. Based on acute lethal
toxicity data and using EC-classification criteria, benzotriazole should be classi-
fied as harmful following inhalation and oral exposure.
No valid repeated-dose short-term toxicity studies were available. From long-
term carcinogenicity studies, there is inconclusive evidence that benzotriazole is
carcinogenic in rats and mice, since these tumours had mostly higher incidences in
the low-dose than in the high-dose group, and occurred at fairly high rates in
historical controls. A NOAEL could not be established since effects were obser-
ved in rats (neoplastic effects: brain tumours in males, thyroid tumours in females;
nonneoplastic effects: decreased body weight gain, histological changes in the
liver, inflammation of prostate and uterus) and mice (neoplastic effects: lung
tumours in females; nonneoplastic effects: decreased body weight gain, bone
marrow myelofibrosis, haemorrhages in mesenteric lymph nodes) at the lowest
dose tested. The LOAELs were set at 295 and 1455 mg/kg bw/d in rats and mice,
respectively.
In vitro, benzotriazole is mutagenic in Salmonella typhimurium TA 1535 and in
E. coli, but not in Chinese hamster ovary cells. The SOS chromotest in E. coli, an
indicator test for DNA damage was negative. In vivo, benzotriazole was negative
in an oral mouse bone marrow micronucleus assay.
There were no valid data on reproduction toxicity.
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7. Existing guidelines, standards and evaluations
7.1 General population
No guidelines for the general population were found.
7.2 Working population
No occupational exposure limits/standards for benzotriazole were established or
recommended in the Netherlands, the Nordic countries, the UK, or by the
American Conference of Governmental Industrial Hygienists (ACGIH). In
Germany, benzotriazole was listed among those compounds for which no limit
could be established (13).
In 1988, Germany concluded that occupational exposure to benzotriazole could
be irritating to the eyes, but not to the skin. Sensitisation may occur. Cytostatic
effects were induced at such high dose levels that these effects are concluded not
to occur at workplace exposure conditions. Since (reversible) central nervous
system effects following single oral or inhalation exposure were induced at rela-
tively high levels and since the dose-response curve might be steep, acute toxic
effects are not expected from using/handling benzotriazole-containing products
(namely, coolant lubricants which contain 0.05% benzotriazole). Toxic effects
following long-term exposure could not be evaluated conclusively, since there
were no data available from (semi)chronic inhalation studies or from reproduction
toxicity studies. On the other hand, significant toxic effects (decreased body
weight gain) were induced at only relatively high dietary levels. Carcinogenic
effects might occur at high doses, although animal experiments were inconclusive.
Benzotriazole would be a weak carcinogen only (17).
8. Hazard assessment
8.1 Assessment of health hazard
Based on experimental animal data with benzotriazole of unknown purity and
limited human data, it is concluded that benzotriazole is slightly irritating to the
eyes and, at most, slightly irritating to the skin Benzotriazole is considered not to
be a skin sensitiser.
Based on acute lethal toxicity data and using EC-classification criteria, benzo-
triazole should be classified as harmful following inhalation and oral exposure.
No data from valid repeated-dose short-term toxicity or developmental toxicity
studies were found.
Benzotriazole was mutagenic in in vitro bacterial cells, but not in mammalian
cell systems. The bacterial test indicator for DNA damage was negative. In vivo,
benzotriazole did not induce micronuclei in the bone marrow of orally treated
mice.
In oral carcinogenicity studies in rats and mice, higher incidences of - mostly
benign - tumours in some organs were observed in treated than in concurrent
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control animals. These tumours had mostly higher incidences in low-dose than in
high-dose groups, and occurred at fairly high rates in historical controls. The
results of these studies are inconclusive with respect to carcinogenic potential of
benzotriazole. No NOAEL can be assessed from these studies since several effects
were observed in rats (neoplastic effects: brain tumours in males, thyroid tumours
in females; nonneoplastic effects: decreased body weight gain, histological
changes in the liver, inflammation of prostate and uterus) and mice (neoplastic
effects: lung tumours in females; nonneoplastic effects: decreased body weight
gain, bone marrow myelofibrosis, haemorrhages in mesenteric lymph nodes) at
the lowest dose tested. The LOAELs were set at 295 and 1455 mg/kg bw/day in
rats and mice, respectively.
In view of the (inconclusive) evidence on the carcinogenic potential of benzo-
triazole in rodents and the mutagenic effects of benzotriazole in bacterial systems
along with the absence of mutagenic and genotoxic effects in mammalian cells
and in mouse bone marrow in vivo, the data base is considered inconclusive
regarding carcinogenicity of this chemical. Thus, benzotriazole should be consid-
ered as a suspected human carcinogen.
Benzotriazole appeared to be a slight eye irritant in experimental animals. This
may indicate that eye and/or respiratory tract irritation cannot be excluded to
occur in workers exposed to benzotriazole. Since no eye irritation studies in
humans were available, and repeated-dose inhalation toxicity studies in experi-
mental animals were absent, it is not possible to derive any LOAEL or NOAEL
for these effects.
8.2 Groups at extra risk
No specific groups at extra risk are identified in the literature.
9. Recommendations for research
• Genotoxicity: a gene mutation test and a chromosome aberration assay
using eukaryotic cells and depending on the results an appropriate in vivo
test.
• Reproduction toxicity studies.
• Subchronic and chronic inhalation toxicity studies in rats.
• A human volunteer respiratory and dermal irritation test.
16
10. Summary
H. Stouten, A.A.J.J.L Rutten, I.A. van de Gevel, and F. De Vrijer.
The Nordic Expert Group for Criteria Documentation of Health Risks from
Chemicals and The Dutch Expert Committee on Occupational Standards.
126. 1,2,3-Benzotriazole. Arbete och Hälsa 2000;24:1-20. National Institute for
Working Life, Solna.
Benzotriazole is an odourless, white to tannish crystalline powder. It is sparingly
soluble in water and soluble in a number of organic solvents. It has a low vapour
pressure, and it is therefore likely to occur as dust at the workplace. When finely
divided and mixed with air, dust explosions may occur. Benzotriazole is an
industrial compound primarily used as a corrosion inhibitor, as a plastic stabiliser,
and as a chemical intermediate. There is very little information found with respect
to the toxicokinetics of benzotriazole.
Based on experimental animal data with benzotriazole of unknown purity and
limited human data, it is concluded that benzotriazole is slightly irritating to the
eyes and, at most, slightly irritating to the skin Benzotriazole is considered not to
be a skin sensitiser.
In the carcinogenicity studies, higher incidences of - mostly benign - tumours in
some organs were observed in treated than in concurrent control animals. These
tumours had mostly higher incidences in the low-dose than in the high-dose
group, and occurred at fairly high rates in historical controls. The LOAELs were
set at 295 and 1455 mg/kg bw/day in rats and mice, respectively.
In view of the inconclusive evidence for carcinogenic potential of benzotriazole
in rodents and the mutagenic effects of benzotriazole in bacterial systems along
with the absence of mutagenic and genotoxic effects in vitro in mammalian cells
and in vivo in experimental animals, the data base is too poor to justify a
conclusion regarding genotoxicity and carcinogenicity of this chemical.
Keywords: benzotriazole, irritation, occupational exposure limit, risk assessment,
toxicology
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11. Summary in Swedish
H. Stouten, A.A.J.J.L Rutten, I.A. van de Gevel, and F. De Vrijer.
The Nordic Expert Group for Criteria Documentation of Health Risks from
Chemicals and The Dutch Expert Committee on Occupational Standards.
126. 1,2,3-Benzotriazole. Arbete och Hälsa 2000;24:1-20. National Institute for
Working Life, Solna.
Bensotriazol är ett luktlöst, vitt till ljusbrunt kristallint pulver. Det är svårlösligt i
vatten men lösligt i många organiska lösningsmedel. Ämnet har lågt ångtryck och
förekommer därför troligen som damm i arbetsmiljön. När det finfördelas och
blandas med luft finns risk för dammexplosioner. Bensotriazol är en industri-
kemikalie som framför allt används för att förhindra korrosion, som stabiliserare i
plaster och som kemisk intermediär. Informationen om upptag och omsättning av
bensotriazol är mycket sparsam.
Baserat på djurförsök med bensotriazol av okänd renhet och på begränsade
humandata får bensotriazol anses vara svagt irriterande på ögon, och som mest,
något irriterande på hud. Bensotriazol anses inte vara hudsensibiliserande.
I cancerstudier observerades en högre incidens av - huvudsakligen godartade -
tumörer i vissa organ hos de behandlade djuren jämfört med de jämsides löpande
kontrolldjuren. Tumörerna hade vanligen en högre incidens i lågdos- än i högdos-
gruppen, och förekom med relativt hög frekvens hos de historiska kontrollerna.
LOAEL-värdena var 295 och 1455 mg/kg kroppsvikt/dag hos råtta respektive
mus.
På grund av icke-konklusiva data vad gäller bensotriazols carcinogena potential
hos gnagare samt ämnets mutagena effekt i bakteriesystem i kombination med
frånvaron av mutagena och genotoxiska effekter in vitro i däggdjursceller och in
vivo hos försöksdjur kan inga slutsatser dras vad gäller bensotriazols genotoxicitet
och carcinogenicitet.
Nyckelord: bensotriazol, hygieniskt gränsvärde, irritation, riskbedömning,
toxikologi
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13. Data bases used in search for literature
For the preparation of this document, literature has been retrieved from online
data bases such as Medline, Toxline and CA (last update online search: May
1998). HSDB and RTECS, data bases available from CD-ROM, were consulted as
well (26, 27).
Conclusions are based on scientific publications prior to March 2000.
Before finalising the document, an additional literature search was performed in
Medline (May 1998 - August 2000) and Toxline (May 1998 - April 2000). The
results of this search were no reason for adjustment of the recommendations.
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